Development
Bial ends development of GCase activator pariceract in Parkinson's after Phase II fail
Portugal-based Bial reported that pariceract (BIA 28-6156; formerly LTI-291, LTI-00291), its oral small-molecule allosteric activator of...
Chugai's ALK-targeting AQUA07 enters Phase I for ALK-positive NSCLC, combined with lorlatinib
Chugai enters first-in-human territory with AQUA07 in ALK-positive NSCLC, pairing novel oral agent with lorlatinib
Alnylam puts siRNA with undisclosed-target into Phase I for obesity management
Alnylam Pharmaceuticals (Nasdaq: ALNY) has initiated a first-in-human Phase I trial of ALN-6222, an investigational siRNA therapeutic administered...
BeOne/Huahui Health's trispecific antibody targeting PD-1, CTLA-4, and VEGF-A enters the clinic
Beijing-based Huahui Health has initiated a first-in-human trial of HH160, a potential first-in-class trispecific antibody engineered to block PD-1, CTLA-4,...
Gilead and Merck to seek approval for HIV combo after positive Phase III
Gilead Sciences (Nasdaq: GILD) and Merck (NYSE: MRK) reported that the investigational islatravir lenacapavir HIV treatment met its primary efficacy...
Merck, Gilead rein in ambitions for Trodelvy in lung cancer after Phase III stumble
Merck (NYSE: MRK) and Gilead Sciences (Nasdaq: GILD) announced the discontinuation of the Phase III KEYNOTE-D46/EVOKE-03 study after sacituzumab govitecan —...
Innovent's IBI3031 bispecific IGF-1R/TSHR antibody enters Phase I for thyroid eye disease
Innovent Moves IBI3031 into First-in-Human Testing with a Bispecific Strategy for Thyroid Eye Disease
ADA: Eli Lilly shows off triple-G agonist retatrutide's strength in obesity
Eli Lilly and Company (NYSE: LLY) reported pivotal Phase III data for retatrutide, its investigational GIP, GLP-1, and glucagon triple hormone receptor...
ADA: Novo Nordisk posts more data for zenagamtide in Phase II for T2D
Novo Nordisk reported positive Phase II results for zenagamtide (also known as amycretin) in type 2 diabetes at the ADA 2026 Scientific Sessions, with the...
Oricell's GPC3 CAR-T advances to Phase II trial in hepatocellular carcinoma
Shanghai-based Oricell Therapeutics Holdings Limited announced that its GPC3 CAR-T therapy, Ori-C101, has received clearance from China's National Medical...
Sanofi and Kymera's second-generation IRAK4 degrader enters Phase I for hidradenitis suppurativa
Sanofi has initiated a first-in-human study of SAR447971 (also known as KT-485), an oral small-molecule IRAK4 targeted protein degrader discovered by...
Tango and Revolution Med's PRMT+RAS(ON) regimen achieves 92% response rate in pancreatic cancer
Early-stage combination data from Boston-based Tango Therapeutics (Nasdaq: TNGX) reported a 92% objective response rate for vopimetostat, its oral...
Boehringer posts detailed data from survodutide Phase III showing visceral and liver fat reduction
Boehringer Ingelheim reported detailed Phase III results for survodutide (BI 456906), a glucagon/GLP-1 receptor dual agonist licensed from Denmark-based...
Hangzhou Sciwind's cAMP-biased GLP-1 ecnoglutide outperforms semaglutide in Phase II
Interim data from a Phase II head-to-head trial reported by China-based Hangzhou Sciwind Biosciences show that ecnoglutide (also known as XW003), the...
Autobahn on track for novel thyroid receptor agonist against bipolar depression after positive Phase II
San Diego-based Autobahn Therapeutics reported positive topline results from its Phase II AMPLIFY-BD trial of elunetirom (ABX-002) in bipolar depression,...
The AllSci Brief
Systematic R&D and deal news. Daily.